Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with <i>EGFR</i>-Mutant Lung Cancer

CTC analysis using CCM-CTCD shows potential as a biomarker for predicting treatment response and prognosis in EGFR-mutant NSCLC. Stratification by CTC molecular response may inform risk-adapted treatment; however, its clinical utility remains to be established. Prospective studies are warranted to validate these findings and determine the role of CTC-guided decision-making.